The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2010 on the treatment of acute bipolar depression

Heinz Grunze, Eduard Vieta, Guy M. Goodwin, Charles Bowden, Rasmus W. Licht, Hans Jrgen Mller, Siegfried Kasper

Research output: Contribution to journalArticle

256 Citations (Scopus)

Abstract

Objectives. These guidelines are based on a first edition that was published in 2002, and have been edited and updated with the available scientific evidence until September 2009. Their purpose is to supply a systematic overview of all scientific evidence pertaining to the treatment of acute bipolar depression in adults. Methods. The data used for these guidelines have been extracted from a MEDLINE and EMBASE search, from the clinical trial database clinicaltrials.gov, from recent proceedings of key conferences, and from various national and international treatment guidelines. Their scientific rigor was categorised into six levels of evidence (AF). As these guidelines are intended for clinical use, the scientific evidence was finally assigned different grades of recommendation to ensure practicability. Results. We identified 10 pharmacological monotherapies or combination treatments with at least limited positive evidence for efficacy in bipolar depression, several of them still experimental and backed up only by a single study. Only one medication was considered to be sufficiently studied to merit full positive evidence. Conclusions. Although major advances have been made since the first edition of this guideline in 2002, there are many areas which still need more intense research to optimize treatment. The majority of treatment recommendations is still based on limited data and leaves considerable areas of uncertainty.

Original languageEnglish (US)
Pages (from-to)81-109
Number of pages29
JournalWorld Journal of Biological Psychiatry
Volume11
Issue number2
DOIs
StatePublished - 2010

Fingerprint

Biological Psychiatry
Bipolar Disorder
Guidelines
MEDLINE
Uncertainty
Clinical Trials
Databases
Pharmacology
Research

Keywords

  • Acute treatment
  • Antidepressants
  • Antipsychotics
  • Bipolar disorder
  • Depression
  • Electroconvulsive therapy
  • Evidence-based guidelines
  • Mood stabiliser
  • Pharmacotherapy
  • Psychotherapy

ASJC Scopus subject areas

  • Biological Psychiatry
  • Psychiatry and Mental health

Cite this

The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders : Update 2010 on the treatment of acute bipolar depression. / Grunze, Heinz; Vieta, Eduard; Goodwin, Guy M.; Bowden, Charles; Licht, Rasmus W.; Mller, Hans Jrgen; Kasper, Siegfried.

In: World Journal of Biological Psychiatry, Vol. 11, No. 2, 2010, p. 81-109.

Research output: Contribution to journalArticle

Grunze, Heinz ; Vieta, Eduard ; Goodwin, Guy M. ; Bowden, Charles ; Licht, Rasmus W. ; Mller, Hans Jrgen ; Kasper, Siegfried. / The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders : Update 2010 on the treatment of acute bipolar depression. In: World Journal of Biological Psychiatry. 2010 ; Vol. 11, No. 2. pp. 81-109.
@article{b8703f1f30ec483ebc7905276a662032,
title = "The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2010 on the treatment of acute bipolar depression",
abstract = "Objectives. These guidelines are based on a first edition that was published in 2002, and have been edited and updated with the available scientific evidence until September 2009. Their purpose is to supply a systematic overview of all scientific evidence pertaining to the treatment of acute bipolar depression in adults. Methods. The data used for these guidelines have been extracted from a MEDLINE and EMBASE search, from the clinical trial database clinicaltrials.gov, from recent proceedings of key conferences, and from various national and international treatment guidelines. Their scientific rigor was categorised into six levels of evidence (AF). As these guidelines are intended for clinical use, the scientific evidence was finally assigned different grades of recommendation to ensure practicability. Results. We identified 10 pharmacological monotherapies or combination treatments with at least limited positive evidence for efficacy in bipolar depression, several of them still experimental and backed up only by a single study. Only one medication was considered to be sufficiently studied to merit full positive evidence. Conclusions. Although major advances have been made since the first edition of this guideline in 2002, there are many areas which still need more intense research to optimize treatment. The majority of treatment recommendations is still based on limited data and leaves considerable areas of uncertainty.",
keywords = "Acute treatment, Antidepressants, Antipsychotics, Bipolar disorder, Depression, Electroconvulsive therapy, Evidence-based guidelines, Mood stabiliser, Pharmacotherapy, Psychotherapy",
author = "Heinz Grunze and Eduard Vieta and Goodwin, {Guy M.} and Charles Bowden and Licht, {Rasmus W.} and Mller, {Hans Jrgen} and Siegfried Kasper",
year = "2010",
doi = "10.3109/15622970903555881",
language = "English (US)",
volume = "11",
pages = "81--109",
journal = "World Journal of Biological Psychiatry",
issn = "1562-2975",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders

T2 - Update 2010 on the treatment of acute bipolar depression

AU - Grunze, Heinz

AU - Vieta, Eduard

AU - Goodwin, Guy M.

AU - Bowden, Charles

AU - Licht, Rasmus W.

AU - Mller, Hans Jrgen

AU - Kasper, Siegfried

PY - 2010

Y1 - 2010

N2 - Objectives. These guidelines are based on a first edition that was published in 2002, and have been edited and updated with the available scientific evidence until September 2009. Their purpose is to supply a systematic overview of all scientific evidence pertaining to the treatment of acute bipolar depression in adults. Methods. The data used for these guidelines have been extracted from a MEDLINE and EMBASE search, from the clinical trial database clinicaltrials.gov, from recent proceedings of key conferences, and from various national and international treatment guidelines. Their scientific rigor was categorised into six levels of evidence (AF). As these guidelines are intended for clinical use, the scientific evidence was finally assigned different grades of recommendation to ensure practicability. Results. We identified 10 pharmacological monotherapies or combination treatments with at least limited positive evidence for efficacy in bipolar depression, several of them still experimental and backed up only by a single study. Only one medication was considered to be sufficiently studied to merit full positive evidence. Conclusions. Although major advances have been made since the first edition of this guideline in 2002, there are many areas which still need more intense research to optimize treatment. The majority of treatment recommendations is still based on limited data and leaves considerable areas of uncertainty.

AB - Objectives. These guidelines are based on a first edition that was published in 2002, and have been edited and updated with the available scientific evidence until September 2009. Their purpose is to supply a systematic overview of all scientific evidence pertaining to the treatment of acute bipolar depression in adults. Methods. The data used for these guidelines have been extracted from a MEDLINE and EMBASE search, from the clinical trial database clinicaltrials.gov, from recent proceedings of key conferences, and from various national and international treatment guidelines. Their scientific rigor was categorised into six levels of evidence (AF). As these guidelines are intended for clinical use, the scientific evidence was finally assigned different grades of recommendation to ensure practicability. Results. We identified 10 pharmacological monotherapies or combination treatments with at least limited positive evidence for efficacy in bipolar depression, several of them still experimental and backed up only by a single study. Only one medication was considered to be sufficiently studied to merit full positive evidence. Conclusions. Although major advances have been made since the first edition of this guideline in 2002, there are many areas which still need more intense research to optimize treatment. The majority of treatment recommendations is still based on limited data and leaves considerable areas of uncertainty.

KW - Acute treatment

KW - Antidepressants

KW - Antipsychotics

KW - Bipolar disorder

KW - Depression

KW - Electroconvulsive therapy

KW - Evidence-based guidelines

KW - Mood stabiliser

KW - Pharmacotherapy

KW - Psychotherapy

UR - http://www.scopus.com/inward/record.url?scp=77649207564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649207564&partnerID=8YFLogxK

U2 - 10.3109/15622970903555881

DO - 10.3109/15622970903555881

M3 - Article

C2 - 20148751

AN - SCOPUS:77649207564

VL - 11

SP - 81

EP - 109

JO - World Journal of Biological Psychiatry

JF - World Journal of Biological Psychiatry

SN - 1562-2975

IS - 2

ER -